Abstract
Alzheimer’s disease (AD) and Parkinson’s disease (PD) are neurodegenerative diseases (NDD) characterized by progressive degeneration of the central nervous system, and few medications are available to halt the progression of AD and PD. In the present study, an engineered strain MG136-pMG36e-GLP-1 was used to evaluate its neuroprotective effect on AD and PD mice, via the probiotics effects of Lactococcus lactis MG1363 and the constantly produced Glucagon-like peptide-1 (GLP-1) by the engineered strain. Our results indicated that oral administration of MG136-pMG36e-GLP-1 significantly reduced lipopolysaccharide (LPS)-induced memory impairment and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced motor dysfunction through the toll-like receptor4 (TLR4)/nuclear factor-kappa B (NFκB) and protein kinase B (AKT)/Glycogen synthase kinase-3β (GSK3β) signaling pathway. High-throughput sequencing results showed that MG1363-pMG36e-GLP-1 reduced the abundance of the pathogens Enterococcus, Proteus, and increased the abundance of the probiotics Akkermansia muciniphila. These results suggest that the engineered strain may be a new intervention for treating AD and PD by reducing the occurrence of neuroinflammation.
Highlights
Neurodegenerative diseases (NDD) are a group of diseases caused by chronic progressive degeneration of the central nervous system, e.g. Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD)
The five groups were: (1) a control group treated with saline (C), (2) a group treated by LPS injection intraperitoneally for 7 days for 0.25 mg/kg body weight per day (AD), (3) the AD mice pretreated with MG1363-pMG36e-Glucagon-like peptide-1 (GLP-1) (AD-G), (4) a group treated by MPTP injection intraperitoneally for 7 days for 20 mg/kg body weight per day (PD), (5) The PD mice pretreated with MG1363-pMG36e-GLP-1 (PD-G)
AD and PD are diseases caused by degeneration and necrosis of neurons in the central nervous system, which seriously affect the life quality of human
Summary
Neurodegenerative diseases (NDD) are a group of diseases caused by chronic progressive degeneration of the central nervous system, e.g. Alzheimer’s disease (AD), Amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). NDD have various lesions with mostly unclear pathogenesis, some common features of progressive degeneration and necrosis of neurons of NDD have been identified, and it is key to develop drugs to treat NDD via overcoming the limited understanding of their etiology and mechanism (Gitler et al 2017). As the most common NDD, AD and PD greatly affect the quality of life. The pathological features of AD are neurofibrillary tangles caused by tau hyperphosphorylation and deposition of amyloid β (Aβ) in the cortex, hippocampus and amygdala. The main clinical manifestations of AD are progressive memory loss, cognitive dysfunction and language impairment (Du et al 2018).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
